Trials / Completed
CompletedNCT03181893
A Study In Adults With Moderate To Severe Dermatomyositis
A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A Study looking at Investigational drug and Placebo administered to adult Patients with moderate to severe Dermatomyositis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-06823859 low | A humanized immunoglobulin neutralizing antibody |
| DRUG | Placebo Arm | Placebo contains histidine, sucrose, PS80, ethylene diamine, and triacetic acid |
| DRUG | PF-06823859 high | A humanized immunoglobulin neutralizing antibody |
Timeline
- Start date
- 2018-01-23
- Primary completion
- 2022-05-27
- Completion
- 2022-11-28
- First posted
- 2017-06-09
- Last updated
- 2023-09-14
- Results posted
- 2023-09-14
Locations
41 sites across 5 countries: United States, Germany, Hungary, Poland, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03181893. Inclusion in this directory is not an endorsement.